Zeng, Yi https://orcid.org/0000-0001-8306-8323
Lovchykova, Anastasiia https://orcid.org/0009-0008-5895-0259
Akiyama, Tetsuya https://orcid.org/0000-0002-8076-1242
Rayner, Stephanie L.
Maheswari Jawahar, Vidhya https://orcid.org/0000-0002-7232-523X
Liu, Chang
Sianto, Odilia
Guo, Caiwei
Calliari, Anna
Prudencio, Mercedes https://orcid.org/0000-0002-4894-4858
Dickson, Dennis W. https://orcid.org/0000-0001-7189-7917
Petrucelli, Leonard
Gitler, Aaron D. https://orcid.org/0000-0001-8603-1526
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R35NS097263)
U.S. Department of Health & Human Services | National Institutes of Health (U54NS123743)
U.S. Department of Health & Human Services | National Institutes of Health (R01AG064690)
U.S. Department of Health & Human Services | National Institutes of Health (R35NS097273)
U.S. Department of Health & Human Services | National Institutes of Health (P01NS084974)
Article History
Received: 15 January 2024
Accepted: 1 July 2025
First Online: 21 October 2025
Competing interests
: A.D.G. is a scientific founder of Maze Therapeutics, Trace Neuroscience and Lyterian Therapeutics. The other authors declare no competing interests.